Surgical Quality Assurance in Breast, Gastric and Rectal Cancer

Journal of Surgical Oncology

Volumn 84, Issue 3, 2003, Pages 107-112

  Peeters, Koen C M J ^a   Van De Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PROTOCOL; COLORECTAL CANCER; EDITORIAL; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY CONTROL; RECTUM CANCER; RECTUM SURGERY; STOMACH CANCER; STOMACH SURGERY;

BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HEALTH PLAN IMPLEMENTATION; HUMANS; LYMPH NODE EXCISION; MALE; NEOADJUVANT THERAPY; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; RECTAL NEOPLASMS; STOMACH NEOPLASMS; SURGERY; SURVIVAL ANALYSIS;

EID: 0242266899     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10312     Document Type: Editorial

References (58)

1. Meunler F, Horlot JC: EORTC scientific strategy meeting 25-26 March 1999. Eur J Cancer 1999;35:1423-1430.
2. Kouloulias VE, Poortmans PM, Bernler J, et al.: The Quality Assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC): A critical appraisal of 20 years of continuous efforts. Eur J Cancer 2003;39:430-437.
3. Therasse P, De Mulder PH: Quality assurance in medical oncology within the EORTC. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002;38:S152-S154.
4. Obodion E, Haffty DG: Negative margin status improves local control in conservatively managed breast cancer patients. Cancer J Sci Am 2000;6:28-33.
5. Dixon JM, Ravlsekar O, Cunningham M, et al.: Factors affecting outcome of patients with impalpable breast cancer detected by breast screening. Br J Surg 1996;83:997-1001.
6. van Dongen JA, Voogd AC, Fentlman IS, et al.: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143-1150.
7. Bijker N, Rutgers EJ, Peterse JL, et al.: Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol 2001;27:135-140.
8. Graversen HP, Blichert-Toft M, Anderson JA, et al.: Breast cancer: Risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988;14:407-412.
9. Axelsson CK, Mouridson HT, Zedeler K: Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:1415-1418.
10. Ververs JM, Roumen RM, Vingerhoets AJ, et al.: Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer 2001;37:991-999.
11. Hack TF, Cohen L, Katz J, et al.: Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 1999;17:143-149.
12. Schrenk P, Rieger R, Shamlych A, Wayand W: Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000;88:608-614.
13. Estourgic SH, Niowog OE, Valdes Olmos RA, et al.: Eight false negative sentinel node procedures in breast cancer, what went wrong? Eur J Surg Oncol 2003;29:336-340.
14. Gillis CR, Hole DJ: Survival outcome of care by specialist surgeons in breast cancer: A study of 3786 patients in the west of Scotland. BMJ 1996;312:145-148.
15. Salnsbury R, Haward B, Rider L, et al.: Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995;345:1265-1270.
16. Overgaard M, Hansen PS, Overgaard J, et al.: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-955.
17. Ekstrom AM, Hansson LE, Signorello LB, et al.: Decreasing incidence of both major histologic subtypes of gastric adenocarcinoma - A population-based study in Sweden. Br J Cancer 2000;83:391-396.
18. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841.
19. Gunderson LL, Sosin H: Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second for symptomatic look) elinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.
20. van de Velde CJ, Peeters KC: The gastric cancer treatment controversy. J Clin Oncol 2003;21:2234-2236.
21. Nishi M, Omori Y MKe. Japanese classification of gastric carcinoma. Japanese research society for gastric cancer (JRSGC). 1st English edition. Tokyo: Kanchara & Co. 1995. Ref type: Generic.
22. Maruyama K, Okabayashi K, Kinoshita T: Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-425.
23. Cuschieri A, Fayers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995-999.
24. Bonenkamp JJ, Songun J, Hermans J, et al.: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748.
25. Bonenkamp JJ, Hermans J, Sesako M, et al.: Extended lymphnode dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 1999;345:908-914.
26. Cushieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-1530.
27. Degiuli M: Morbidity and mortality after D1 and D2 gastrectomy for cancer: Preliminary results of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial; Oral presentation; Fifth International Gastric Cancer Congress, Rome, Italy, May 4-7, 2003. Ref type: Generic.
28. Deginli M, Sasako M, Pontl A, et al.: Morbidity and mortality after D2 gastroctomy for gastric cancer: Results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol 1998;16:1490-1493.
29. Bottcher K, Siewert JR, Roder JD, et al.: Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group (92). Chirurg 1994;65:298-306.
30. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
31. Hundahl SA, Macdonald JS, Benedetti J, et al.: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. Attn Surg Oncol 2002;9:278-286.
32. Hermans J, Bonenkamp JJ, Boon MC, et al.: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-1447.
33. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-1064.
34. Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dcl Carcinoml dell'Apparato Digerente). Ann Oncol 2000;11:837-843.
35. Panzini I, Gianni L, Fattori PP, et al.: Adjuvant chemotherapy in gastric cancer: A meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002;88:21-27.
36. Bunt TM, Bonenkamp HJ, Hermans J, et al.: Factors influencing noncontupliance and contamination in a randomized trial of "Western" (r1) versus "Japanese" (r2) type surgery in gastric cancer. Cancer 1994;73:1544-1551.
37. Holm T, Cedermark B, Rutqvist LE: Local recurrence of rectal adenocarcinoma after 'curative' surgery with and without preoperative radiotherapy. Br J Surg 1994;81:452-455.
38. MacFariane JK, Ryall RD, Hcald RJ: Mesorectal excision for rectal cancer. Lancer 1993;341:457-460.
39. Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-1472.
40. Fisher B, Wolmark N, Rockette H, et al.: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21-29.
41. Reynolds JV, Joyce WP, Dolan J, et al.: Pathological evidence in support of total mesorectal excision in the management of rectal cancer. Br J Surg 1996;83:1112-1115.
42. Havengs K, Enker WE, McDermott K, et al.: Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll Surg 1996;182:495-502.
43. van Driel MF, Weymar Schultz WC, van de Wiel HB, et al.: Female sexual functioning after radical surgical treatment of rectal and bladder cancer. Eur J Surg Oncol 1993;19:183-187.
44. Petrelli NJ, Nagel S, Rodriguez-Bigas M, et al.: Morbidity and mortality following abdominoperineal resection for rectal adenocarcinoma. Am Surg 1993;59:400-404.
45. Heald RJ: A new approach to rectal cancer. Br J Hosp Med 1979;22:277-281.
46. Enker WE, Thaler HT, Cranor ML, et al.: Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995;181:335-346.
47. Altken RJ: Mesorectal excision for rectal cancer. Br J Surg 1996;83:214-216.
48. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-987.
49. Kapiteijn E, Kranenbarg EK, Stcup WH, et al.: Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group. Eur J Surg 1999;165:410-420.
50. Qulrke P, Durdey P, Dixon MF, et al.: Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2:996-999.
51. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-646.
52. Houbiers JG, Brand A, van de Watering LM, et al.: Randomised controlled trial comparing transfusion of leucocytedepleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344:573-578.
53. Kapiteijn E, Putter H, van de Velde CJ: Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002;89:1142-1149.
54. Martling AL, Holm T, Rutqvist LE, et al.: Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000;356:93-96.
55. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al.: Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: Not one millimeter but two millimeter but two millimeters is the limit. Am J Surg Pathol 2002;26:350-357.
56. Nagtegaal ID, van de Velde CJ, van der WE, et al.: Macroscopic evaluation of rectal cancer resection specimen: Clinical significance of the pathologist in quality control. J Clin Oncol 2002;20:1729-1734.
57. Bects-Tan RG, Beets GL, Vliegen RF, et al.: Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001;357:497-504.
58. Marijnen CA, Nagtegaal ID, Kapiteijn E, et al.: Radiotherapy does not compensate for positive resection margins in rectal cancer patients: Report of a multicenter randomized trial. Int J Radial Oncol Biol Phys 2003;55:1311-1320.